Amyl Therapeutics is a preclinical stage biotechnology company.
Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β (Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jun 3, 2021 | Series A | €8.60M | 7 | Meusinvest (Noshaq) | — | Detail |
Jun 3, 2021 | Grant | €9.70M | 1 | Directorate General operational for Economy, Employment and Research | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Meusinvest (Noshaq) | Yes | Series A |
Directorate General operational for Economy, Employment and Research | Yes | Grant |
Ifoghas Investments | — | Series A |
6K Venture Capital | — | Series A |
Kenneth Buckfire | — | Series A |
Merieux Developpement | — | Series A |
Sambrinvest | — | Series A |
Smedvig | — | Series A |